Important Deadline Approaches for Aquestive Therapeutics Investors in Class Action Lawsuit

Critical Deadline for Aquestive Therapeutics Investors

Overview
Investors in Aquestive Therapeutics, Inc. (NASDAQ: AQST) must be aware of an upcoming legal deadline. Faruqi & Faruqi, LLP, a respected national securities law firm, is actively investigating potential claims against the company. This investigation centers around a federal securities class action, which has a crucial deadline set for May 4, 2026. Investors who acquired shares between June 16, 2025, and January 8, 2026, are particularly encouraged to engage in this process.

The Situation Unfolds
The legal concerns stem from allegations that Aquestive and its executives may have misled investors regarding the state of their New Drug Application (NDA) for Anaphylm. In their communications, the company purportedly failed to disclose significant information about the human factors associated with their sublingual film. Specifically, issues regarding the packaging, administration, and labeling were downplayed, rather than adequately disclosed.

On January 9, 2026, Aquestive's CEO acknowledged that the FDA had identified deficiencies in the NDA, which hindered discussions about labeling and post-marketing commitments. This announcement was impactful, leading to a dramatic decline in Aquestive's stock price, which plummeted by $2.30 per share, representing a 37.04% drop to close at $3.91 per share on that date. Such significant losses raise concern for investors who are now considering their options.

Call to Action
Faruqi & Faruqi encourages impacted investors to reach out to discuss their rights and potential legal remedies. Josh Wilson, a partner at the firm, welcomes direct communication from investors who have suffered losses, preparing them to navigate the complexities of this class action lawsuit.

The key to managing these legal proceedings lies in the role of the lead plaintiff. This individual is critical as they manage the litigation on behalf of the class, ensuring their interests are represented adequately. Any member of the affected group is eligible to apply to serve in this capacity, emphasizing the importance of collective action among investors.

Who Should Participate?
Investors who feel they have been misled or who have suffered financial losses due to Aquestive's alleged conduct should consider joining this class action effort. Whether you choose to take the lead or remain part of the class, your voice adds value to the collective case being presented.

Faruqi & Faruqi also stresses the need for individuals who may have pertinent information regarding the company's activities, such as whistleblowers or former employees, to come forward. Their insights could be invaluable in strengthening the case and ensuring that a comprehensive account of the situation is presented.

Next Steps
For those interested in learning more or getting involved, additional resources are available through Faruqi & Faruqi's website. Investors are encouraged to take the necessary steps before the deadline of May 4, 2026, to ensure their rights are protected and that they have the opportunity to recover potential losses effectively.

Faruqi & Faruqi has a long history of recovering substantial amounts for investors and aims to continue this tradition through diligent representation in this case.

Conclusion
As the legal deadline approaches, it is essential for investors to stay informed and take appropriate action. A proactive approach in joining the class action can help affected investors pursue justice and recover losses caused by what they believe to be misleading corporate practices.